GARDASIL 9 AS A STRATEGY FOR ONCOLOGICAL PREVENTIVE MEDICINE: INTEGRATION BETWEEN IMMUNIZATION, SCREENING, AND REDUCTION OF THE GLOBAL BURDEN OF CERVICAL CANCER

Abstract

This chapter aims to analyze the role of the nine-valent human papillomavirus (HPV) vaccine, commercially known as Gardasil 9, as an oncological preventive medicine strategy, emphasizing its integration with screening programs and public health policies designed to reduce the global burden of cervical cancer. This study consists of a narrative review of national and international scientific literature, adopting a qualitative approach and examining institutional guidelines. The findings indicate that expanding vaccination coverage combined with cytological and molecular screening significantly reduces the incidence of high-grade intraepithelial lesions and mortality associated with cervical cancer. Integrated strategies based on equitable access and health education further enhance immunization outcomes, particularly among vulnerable populations. It is concluded that the systematic incorporation of the nine-valent vaccine into national immunization schedules, aligned with organized screening programs, represents a cost-effective and essential measure to achieve global targets for the elimination of cervical cancer as a public health problem.